The Hereditary Testing Market Size was valued at USD 7.1 Billion in 2023 and is expected to reach USD 14.6 Billion by 2032, growing at a CAGR of 8.3% over the forecast period 2024-2032.
To Get more information on Hereditary Testing Market - Request Free Sample Report
The report provides a comprehensive overview of the hereditary testing market, including the key trends and insights that are shaping the industry. It also analyses incidence and prevalence data, the increasing volume and growth of genetic testing, market penetration by regions, and identifying the leading and emerging markets. The report analyzes healthcare expenditure, detailing government, insurance, and out-of-pocket spending. Moreover, it delves into technological advancements including next-generation sequencing (NGS) and AI-based analysis, which are improving accuracy and reducing costs. It assesses the regulatory and reimbursement environment, gaining independence into approvals, reimbursement trends, and country preferences. These data-driven insights help stakeholders navigate market opportunities and challenges effectively. The hereditary testing market is experiencing significant growth driven by increasing awareness of genetic disorders, advancements in genomic technologies, and rising healthcare expenditure. According to the National Institutes of Health (NIH), approximately 10% of adults in the United States have a rare disease, many of which are genetic in nature.
Drivers
Advancements in genomic technologies have enhanced the accuracy and affordability of hereditary testing.
The rapid development of genomic technologies has closely been associated with the field of hereditary testing, helping improve the accuracy and feasibility of genetic testing. One major milestone is the significant decrease in the cost of whole genome sequencing (WGS). Since the initial mapping of the human genome in 2003, sequencing costs have plummeted from approximately USD 3 billion to under USD 1,000, making genetic testing more attainable for a broader population. In the clinical arena, these technological advances have begun to result in innovative applications. For example, NHS England is running a world-first program to test 100,000 newborns for more than 200 genetic diseases using WGS. At the same time, this initiative seeks to enable early diagnosis and treatment, which could revolutionize patient outcomes. For example, in Queensland Australia, a rapid heel prick test that screens for hundreds of genetic diseases in newborns has been rolled out. It is a sweeping expansion from the previous test, which screened for just 32 disorders, and is available for the first time to 60,000 babies as part of enhanced screening.
Furthermore, the use of artificial intelligence (AI) and machine learning (ML) is helping interpret complex genetic data. Research institutions, such as the Murdoch Children's Research Institute, are using these technologies to address the challenge of diagnosing rare childhood diseases, using AI-driven tools to increase the rate of diagnosis for affected children to as much as 70%. These developments represent a significant evolution in hereditary testing, powered by technological progress and focused healthcare efforts that promise to make genetic diagnostics more accurate and widely available.
Restraints:
Ethical and privacy concerns regarding the collection and use of genetic data may deter individuals from undergoing testing.
Hereditary testing has been greatly restricted due to ethical and privacy concerns. Recent events have amplified public concern about the safety and misuse of genetic data. In October 2023, 23andMe, a prominent genetic testing company, experienced a data breach affecting approximately 6.9 million users. The exposed information consisted of sensitive details like names, birth years, location, and genetic ancestry and raised concerns about how third-party entities could potentially misuse it. Likewise, in October 2024, Nebula Genomics found itself on the receiving end of a federal class-action lawsuit in Chicago. The lawsuit alleged that the company had violated Illinois' Genetic Information Privacy Act by collecting and distributing genetic information without appropriate consent. The lawsuit also targeted large tech companies including Meta, Microsoft, and Google, alleging they had gained from improper access to personal genetic data for advertising.
These cases raise unsettling, unique vulnerabilities of genetic data handling and have contributed to rising public skepticism. A survey conducted in late 2024 found that 68% of respondents were concerned about the privacy of their genetic information, and 52% said they might not take a genetic test if their data could potentially be misused. The growing mistrust poses a major threat to the expansion of the hereditary testing market as people begin to weigh the pros of testing against the cons of their personal privacy.
Opportunities:
The integration of artificial intelligence and machine learning can improve the interpretation of genetic data, leading to more accurate and actionable insights.
The application of AI and ML in genetic testing provides promising potential to improve the precision and efficacy of genomic data interpretation. AI-based tools are capable of processing large and intricate datasets from genomics, unveiling patterns and mutations often too subtle for the human eye to discern. For example, AI has been applied in metagenomic analyses that have been able to identify a wide range of vertebrate hosts and Plasmodium parasites in samples of Anopheles gambiae mosquitoes, enhancing our understanding of vector-borne disease. In 2024, the Nobel Prize in Chemistry went to the creators of AlphaFold, an AI tool that can predict 3D protein structures with stunning accuracy. Revolutionary Implications for Genomics As protein structures are the keys to the locks of gene functions and interactions, this discovery has far-reaching consequences for genomics. The technological advancements in genomic sequencing methods and the growing need for personalized medicine. Companies like Insitro are using A.I. to create novel screenings and treatments for diseases including ALS and cancer. Insitro's goal is to use machine learning to understand genetic samples and extract causal mechanisms that traditional studies in this field often miss, which will expedite the finding of effective therapies.
Challenges:
The high cost of hereditary testing services can be a significant barrier, particularly in developing countries with limited healthcare resources.
The current high price of hereditary testing services is a significant barrier to access, especially in developing countries with inadequate health resources. In India, for instance, the cost of genetic tests ranges from ₹7,000 to ₹80,000, depending on the complexity and type of test. Additionally, most health insurance plans in these areas do not cover genetic testing, meaning the patient pays for a large portion of the cost out of the box. Further, indirect costs including follow-up visits, additional imaging studies, and chronic management of these conditions where applicable add to the economic burden. Unfortunately, this scenario usually creates a gap in access to genetic testing facilities, as a result of which early diagnosis of diseases and personalized treatment are being compromised for many hereditary disorders in populations from resource-constrained regions.
By Disease Type
In 2023, the hereditary non-cancer testing segment dominated the market and accounted for over 79% revenue share of the market. This large share can be credited to several factors such as the high prevalence of non-cancer genetic disorders and increased awareness about prenatal and newborn screening. As per the World Health Organisation (WHO), genetic disorders and congenital anomalies account for nearly 2-5% of all live births worldwide. In the United States, more than 12,000 babies are diagnosed with genetic or congenital disorders each year through newborn screening programs, according to the CDC. According to the National Human Genome Research Institute, more than 7,000 specific genetic disorders have been identified, with new ones emerging every year. This vast number of non-cancer genetic conditions contributes to the segment's dominance. Moreover, governmental initiatives have also significantly contributed to the growth of non-cancer genetic testing. For instance, the U.S. Newborn Screening Saves Lives Reauthorization Act of 2014 has led to comprehensive screening programs across all 50 states, covering at least 31 core conditions. These factors, combined with advancements in testing technologies and increasing public awareness, have solidified the hereditary non-cancer testing segment's leading position in the market.
By Technology
Molecular testing accounted for 54% of the revenue of the market in 2023. This dominance can be attributed to the high accuracy, sensitivity, and specificity of molecular testing techniques in detecting genetic variations. These molecular diagnostics tests have been reported to have a sensitivity and specificity greater than 95% for many genetic disorders (NCBI). Due to their reliability and clinical utility, many molecular diagnostic tests for hereditary conditions have been approved by the U.S. Food and Drug Administration (FDA). Historical data from the National Institutes of Health (NIH) Genetic Testing Registry shows a significant increase in the number of available molecular tests, from approximately 1,000 in 2012 to over 75,000 in 2022, demonstrating the rapid adoption and development of this technology. In addition, the Centers for Medicare & Medicaid Services (CMS) have expanded coverage of molecular diagnostic tests. Such government support has been instrumental in fuelling the growth of the segment. The dominance of the molecular testing segment is also supported by its broad application for detecting a wide variety of genetic alterations including single nucleotide polymorphisms to large chromosomal alterations.
Europe dominated the hereditary testing market with a 35% revenue share in 2023. The region's advanced healthcare infrastructure and a strong focus on genetic research contributed significantly to its market leadership. Many countries in Europe made significant investments in genomic initiatives, like the UK’s 100,000 Genomes Project which catalyzed genetic testing technologies development and adoption. Furthermore, favourable government policies and investment in genetic research created an ecosystem conducive to market expansion. Demand for hereditary testing was also fuelled by the high prevalence of genetic disorders in European populations. For example, the European Cancer Information System estimated by 2035 that there would be 3.13 million new cancer cases in Europe, leading to greater demand for diagnostic genetic testing. In addition, several key players offering genetic tests and the high uptake of advanced treatments in the European region resulted in market dominance in this region. While it varied among countries, the regulatory framework in Europe was generally supportive of the approval and commercialization of tests. This allowed numerous genetic tests to be available at several major companies in the area.
On the other hand, the hereditary testing industry in Asia-Pacific is growing at the highest CAGR. The growth can be attributed to awareness regarding healthcare, disposable income, and government initiatives to enhance access to genetic testing. For example, the Indian Council of Medical Research (ICMR) has set up a genetic testing laboratory network across the country to improve diagnostic capabilities. The Chinese National Health Commission has integrated genetic testing into its national health strategy and promotes it as a part of regular healthcare. In 2023, approximately 25% of the global market share in the Asia-Pacific region was accounted for, indicating substantial potential for growth. This growth is propelled by factors such as large population bases, improving healthcare infrastructure, and increasing prevalence of genetic disorders in countries like India and China. Asian genetic and rare disorder prevalence is greater than the world average (WHO-2023), which makes it necessary to expand genetic testing services in Asia.
Get Customized Report as per Your Business Requirement - Enquiry Now
Key Service Providers/Manufacturers
Invitae Corporation (Invitae Genetic Test, Carrier Screening Test)
Myriad Genetics, Inc. (MyRisk Hereditary Cancer Test, Foresight Carrier Screen)
Quest Diagnostics Incorporated (BRCAvantage, ClariTest Core)
Laboratory Corporation of America Holdings (LabCorp) (Integrated Genetics, Hereditary Cancer Panel)
Illumina, Inc. (TruSight Hereditary Cancer, VeriSeq NIPT Solution)
Thermo Fisher Scientific, Inc. (Ion Torrent Oncomine, CarrierSeq ECS)
23andMe, Inc. (Health + Ancestry Service, Carrier Status Reports)
Fulgent Genetics (Comprehensive Cancer Panel, X-Linked Panel)
Color Health, Inc. (Color Hereditary Cancer Test, Genetic Health Screen)
Bionano Genomics, Inc. (Saphyr System, Genetic Disease Testing Solutions)
Key Users (Hospitals, Research Institutions, and Clinics Using These Services):
Mayo Clinic
Cleveland Clinic
Johns Hopkins Medicine
Memorial Sloan Kettering Cancer Center
Stanford Health Care
MD Anderson Cancer Center
Boston Children's Hospital
National Institutes of Health (NIH)
Cedars-Sinai Medical Center
In June of 2024, Illumina, Inc. introduced its latest high-throughput sequencing platform, purpose-built for large-scale hereditary disease applications. This development was intended to expand testing capacity and shorten turnaround times for genetic diagnoses.
In September 2024, Myriad Genetics announced the launch of a new pan-cancer panel, which tests for genetic mutations that can lead to more than 30 hereditary cancers. This launch was supported by NCI-funded research.
The U.S. National Institutes of Health (NIH) acknowledged the need for a large-scale genomic study of rare hereditary disorders, launching a $500 million, five-year initiative in January 2025 to help improve understanding of these conditions and diagnostic capabilities.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 7.1 Billion |
| Market Size by 2032 | USD 14.6 Billion |
| CAGR | CAGR of 8.3% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Disease Type (Hereditary Cancer Testing {Lung Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Stomach/Gastric Cancer, Uterine Cancer, Melanoma, Sarcoma, Pancreatic Cancer, Others}, Hereditary Non-cancer Testing {Genetic Tests [Cardiac Diseases, Rare Diseases, Other Diseases], Preimplantation Genetic Diagnosis & Screening, Newborn Genetic Screening, Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests}) • By Technology (Cytogenetic, Biochemical, Molecular Testing) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Invitae Corporation, Myriad Genetics, Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings (LabCorp), Illumina, Inc., Thermo Fisher Scientific, Inc., 23andMe, Inc., Fulgent Genetics, Color Health, Inc., Bionano Genomics, Inc. |
Ans. The projected market size for the Hereditary Testing Market is USD 14.6 Billion by 2032.
The CAGR of the Hereditary Testing Market is 8.3% During the forecast period of 2024-2032.
The North American region dominated the Hereditary Testing Market in 2023.
The integration of artificial intelligence and machine learning can improve the interpretation of genetic data, leading to more accurate and actionable insights.
Ans: The Non-Hereditary Cancer Testing Disease Type segment dominated the Hereditary Testing Market.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Genetic Disorders (2023)
5.2 Testing Volume and Growth Trends (2020-2032)
5.3 Healthcare Expenditure on Hereditary Testing (2023)
5.4 Technological Advancements in Testing Methods
5.5 Regulatory and Compliance Landscape
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Hereditary Testing Market Segmentation, By Disease Type
7.1 Chapter Overview
7.2 Hereditary Cancer Testing
7.2.1 Hereditary Cancer Testing Market Trends Analysis (2020-2032)
7.2.2 Hereditary Cancer Testing Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Lung Cancer
7.2.3.1 Lung Cancer Market Trends Analysis (2020-2032)
7.2.3.2 Lung Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Breast Cancer
7.2.4.1 Breast Cancer Market Trends Analysis (2020-2032)
7.2.4.2 Breast Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Cervical Cancer
7.2.5.1 Cervical Cancer Market Trends Analysis (2020-2032)
7.2.5.2 Cervical Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.6 Colorectal Cancer
7.2.6.1 Colorectal Cancer Market Trends Analysis (2020-2032)
7.2.6.2 Colorectal Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.7 Prostate Cancer
7.2.7.1 Prostate Cancer Market Trends Analysis (2020-2032)
7.2.7.2 Prostate Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.8 Ovarian Cancer
7.2.8.1 Ovarian Cancer Market Trends Analysis (2020-2032)
7.2.8.2 Ovarian Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.9 Stomach/Gastric Cancer
7.2.9.1 Stomach/Gastric Cancer Market Trends Analysis (2020-2032)
7.2.9.2 Stomach/Gastric Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.10 Uterine Cancer
7.2.10.1 Uterine Cancer Market Trends Analysis (2020-2032)
7.2.10.2 Uterine Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.11 Melanoma
7.2.11.1 Melanoma Market Trends Analysis (2020-2032)
7.2.11.2 Melanoma Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.12 Sarcoma
7.2.12.1 Sarcoma Market Trends Analysis (2020-2032)
7.2.12.2 Sarcoma Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.13 Pancreatic Cancer
7.2.13.1 Pancreatic Cancer Market Trends Analysis (2020-2032)
7.2.13.2 Pancreatic Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.14 Others
7.2.14.1 Others Market Trends Analysis (2020-2032)
7.2.14.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Hereditary Non-cancer Testing
7.3.1 Hereditary Non-cancer Testing Market Trends Analysis (2020-2032)
7.3.2 Hereditary Non-cancer Testing Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Genetic Tests
7.3.3.1 Genetic Tests Market Trends Analysis (2020-2032)
7.3.3.2 Genetic Tests Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.3 Cardiac Diseases
7.3.3.3.1 Cardiac Diseases Market Trends Analysis (2020-2032)
7.3.3.3.2 Cardiac Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.4 Rare Diseases
7.3.3.4.1 Rare Diseases Market Trends Analysis (2020-2032)
7.3.3.4.2 Rare Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.5 Other Diseases
7.3.3.5.1 Other Diseases Market Trends Analysis (2020-2032)
7.3.3.5.2 Other Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Preimplantation Genetic Diagnosis & Screening
7.3.4.1 Preimplantation Genetic Diagnosis & Screening Market Trends Analysis (2020-2032)
7.3.4.2 Preimplantation Genetic Diagnosis & Screening Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5 Newborn Genetic Screening
7.3.5.1 Newborn Genetic Screening Market Trends Analysis (2020-2032)
7.3.5.2 Newborn Genetic Screening Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.6 Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
7.3.6.1 Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests Market Trends Analysis (2020-2032)
7.3.6.2 Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Hereditary Testing Market Segmentation, By Technology
8.1 Chapter Overview
8.2 Cytogenetic
8.2.1 Cytogenetic Market Trends Analysis (2020-2032)
8.2.2 Cytogenetic Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Biochemical
8.3.1 Biochemical Market Trends Analysis (2020-2032)
8.3.2 Biochemical Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Molecular Testing
8.4.1 Molecular Testing Market Trends Analysis (2020-2032)
8.4.2 Molecular Testing Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Hereditary Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.2.4 North America Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.2.5.2 USA Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.2.6.2 Canada Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.2.7.2 Mexico Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Hereditary Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.1.5.2 Poland Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.1.6.2 Romania Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Hereditary Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.4 Western Europe Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.5.2 Germany Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.6.2 France Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.7.2 UK Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.8.2 Italy Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.9.2 Spain Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.12.2 Austria Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Hereditary Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.4.4 Asia Pacific Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.4.5.2 China Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.4.5.2 India Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.4.5.2 Japan Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.4.6.2 South Korea Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.2.7.2 Vietnam Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.4.8.2 Singapore Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.4.9.2 Australia Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Hereditary Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.1.4 Middle East Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.1.5.2 UAE Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Hereditary Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.2.4 Africa Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Hereditary Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.6.4 Latin America Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.6.5.2 Brazil Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.6.6.2 Argentina Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.6.7.2 Colombia Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Hereditary Testing Market Estimates and Forecasts, By Disease Type (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Hereditary Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10. Company Profiles
10.1 Invitae Corporation
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Myriad Genetics, Inc.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Quest Diagnostics Incorporated
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Laboratory Corporation of America Holdings (LabCorp)
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Illumina, Inc.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Thermo Fisher Scientific, Inc.
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 23andMe, Inc.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Fulgent Genetics
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Color Health, Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Bionano Genomics, Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Disease Type
Hereditary Cancer Testing
Lung Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Stomach/Gastric Cancer
Uterine Cancer
Melanoma
Sarcoma
Pancreatic Cancer
Others
Hereditary Non-cancer Testing
Genetic Tests
Cardiac Diseases
Rare Diseases
Other Diseases
Preimplantation Genetic Diagnosis & Screening
Newborn Genetic Screening
Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
By Technology
Cytogenetic
Biochemical
Molecular Testing
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Pharma 4.0 Market was valued at 12.72 Bn in 2023 and is expected to reach 47.17 Bn by 2031, and grow at CAGR of 17.8% by forecast period 2024-2031.
The Cardiology Information System (CIS) Market Size was valued at USD 1.09 billion in 2023 and is expected to reach USD 2.24 billion by 2031 and grow at a CAGR of 9.4% over the forecast period 2024-2031.
The Mass Spectrometry in Precision Medicine Market is growing significantly and is expected to expand at a CAGR of around 8.01% from 2024-2032.
The Prenatal Care Market Size was valued at USD 3.90 Billion in 2023 and is expected to reach USD 6.65 Billion by 2032, growing at a CAGR of 6.10% over the forecast period of 2024-2032.
The Hospital Outsourcing Market Size was valued at USD 347.8 Billion in 2023 and is projected to grow to USD 824.5 Billion by 2032, with a CAGR of 10.1%.
The Health Insurance Exchange Market size was valued at USD 2514.41 billion in 2023 and is expected to reach USD 4940.38 billion by 2032, growing at a CAGR of 7.82% over 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
